AzTrials
AzTrials

Respiratory InsufficiencyPhase 4NCT05024799

Effect of Different Sedation and Analgesia Strategies on Patients With Mechanical Ventilation

A Phase 4 study testing Fentanyl, propofol, fentanyl and dexmedetomindine and Butorphanol and propofol in people with Respiratory Insufficiency, run by The Affiliated Hospital of Qingdao University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Most patients in ICU are treated with a combination of analgesics and sedatives in most cases. Due to the different mechanism of different sedative and analgesic drugs, different antagonistic or synergistic effects may occur when combined with drugs, resulting in different clinical effects, especially significant… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Respiratory Insufficiency
What is being tested?
Fentanyl, propofol, fentanyl and dexmedetomindine and Butorphanol and propofol
Could I receive a placebo?
No, everyone receives an active treatment
How many people
300 participants
Where
No sites listed yet
Study dates
Jan 2022to Dec 2024
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults who are treated with sedation and analgesia for invasive mechanical ventilation

Who cannot join

  • they have baseline severe cognitive impairment; were pregnant or breast-feeding; were blind, deaf ; had second-degree or third-degree heart block or bradycardia requiring intervention; had an allergy to the experimental drugs; had an indication for benzodiazepines; were anticipated to have immediate discontinuation of mechanical ventilation; were expected to have neuromuscular blockade for more than 48 hours; were in a moribund state; or had received mechanical ventilation for more than 96 hours before meeting all inclusion criteria.

Trial locations and contacts

No sites are listed yet.

About this study

Most patients in ICU are treated with a combination of analgesics and sedatives in most cases. Due to the different mechanism of different sedative and analgesic drugs, different antagonistic or synergistic effects may occur when combined with drugs, resulting in different clinical effects, especially significant effects on ventilators for patients with assisted breathing. Therefore, this study hopes to compare the effects of different sedative and analgesic drug combinations on the duration of mechanical ventilation for patients with ventilators, so as to guide the clinical adoption of a more reasonable sedative and analgesic scheme.

Being tested
Fentanyl, propofol, fentanyl and dexmedetomindine, Butorphanol and propofol, Butorphanol and dexmedetomindine
Medical subject headings
Respiratory Insufficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fentanyl, propofolDrug

    The patients in this group will be administered with fentanyl and propofol

  • fentanyl and dexmedetomindineDrug

    The patients in this group will be administered with fentanyl and dexmedetomindine

  • Butorphanol and propofolDrug

    The patients in this group will be administered with butorphanol and propofol

  • Butorphanol and dexmedetomindineDrug

    The patients in this group will be administered with butorphanol and dexmedetomindine

Study groups in NCT05024799
Study groupRoleWhat they receive
F-P groupExperimentalthe combination of fentanyl and propofol
Receives: Drug: Fentanyl, propofol
F-D groupExperimentalthe combination of fentanyl and dexmedetomidine
Receives: Drug: fentanyl and dexmedetomindine
B-P groupExperimentalthe combination of butorphanol and propofol
Receives: Drug: Butorphanol and propofol
B-D groupExperimentalthe combination of butorphanol and dexmedetomidine
Receives: Drug: Butorphanol and dexmedetomindine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. ventilator-free days at 28 days

    Measured: at 28 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Aug 2021
  2. Study startJan 2022 (estimated)
  3. Primary completionDec 2024 (estimated)
  4. Study completionDec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
300 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05024799
Sponsor's protocol ID
QYFYKYLL931311920
Status last verified
Aug 2021
First submitted
23 Aug 2021
Last updated
27 Aug 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Fentanyl, propofol, fentanyl and dexmedetomindine and Butorphanol and propofol in people with Respiratory Insufficiency, run by The Affiliated Hospital of Qingdao University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 27 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Jinyan Xing, Dr (86-0532-82919386 ext. 82919386, xingjy@qdu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

ventilator-free days at 28 days (time frame: at 28 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in